Hester Biosciences Limited

NSE:HESTERBIO.NS

2496.55 (INR) • At close November 13, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12012 Q42012 Q32012 Q22012 Q1
Revenue 836.92822.67792.55669.83704.55878.53672.99749.44731.53506.95564.69556.89626.62601.86641.75568.94534.1398.53436.204506.92441.98447.58497.538457.32427.73398.08170.233187.01155.35138.43
Cost of Revenue 245.17435.7413.85206.39195.26341.71219.18198.18213.94143.56215.37133.07161.52178.59238.26136.77139.2949.61313.557.0255.7655.75350.49271.2945.4256.9475.42166.9256.1749.23
Gross Profit 591.75386.97378.7463.44509.29536.82453.81551.26517.59363.39349.32423.82465.1423.27403.49432.17394.81348.92122.704449.9386.22391.83147.046386.03382.31341.1494.811120.0999.1889.2
Gross Profit Ratio 0.7070.470.4780.6920.7230.6110.6740.7360.7080.7170.6190.7610.7420.7030.6290.760.7390.8760.2810.8880.8740.8750.2960.8440.8940.8570.5570.6420.6380.644
Reseach & Development Expenses 0046.6500033.9400000000000000031.7420000000
General & Administrative Expenses 00168.84000108.53000155.6000131.49000131.970000000024.161919.92
Selling & Marketing Expenses 0088.0600099.7400049.6300037.96000123.3200000000000
SG&A 241.2251.81256.9206.08212.65159.98208.27217.53239.16118.47205.23106.6111.17139.7169.45107.9184.285.67255.29102.6793.5686.1681.57473.0367.567.37-19.24524.161919.92
Other Expenses 012.2541.459.943.5811.4531.8843.9144.4931.23-59.9327.7714.2423.48-11.5612.712.436.94-6.593.026.975.75-6.0652.664.777.2189.75636.1230.9627.83
Operating Expenses 241.2251.81256.9399.38419.98447.18390.71416.07440.44339.69166.67325.21320.03284.87207.86253.06269.2261.6734.801277.12307.95248.37-55.534211.17261.04215.1970.5160.2849.9647.75
Operating Income 149.59135.16121.886.04148.38101.0997.95198.88127.2754.93102.86126.38159.31138.4195.63179.11125.6187.2587.903172.7878.27143.46202.58174.86121.27125.9524.30159.8149.2241.45
Operating Income Ratio 0.1790.1640.1540.1280.2110.1150.1460.2650.1740.1080.1820.2270.2540.230.3050.3150.2350.2190.2020.3410.1770.3210.4070.3820.2840.3160.1430.320.3170.299
Total Other Income Expenses Net -30.91-29.24-23.13-253.42-320.75-0.52-61.3624.7925.5730.93-69.56-9.62-7.4214.88-56.97-2.51-18.68-8.41-25.491-23.27-7.15-13.24-25.459-7.95-16.9-5.79-7.586-8.34-8.34-6.46
Income Before Tax 118.6897.3293.8664.1167.6389.1284.21159.98102.7254.63113.09116.76151.89153.28138.66176.6106.9378.8462.412149.5171.12130.22177.121166.91104.37120.1616.71551.4740.8834.99
Income Before Tax Ratio 0.1420.1180.1180.0960.0960.1010.1250.2130.140.1080.20.210.2420.2550.2160.310.20.1980.1430.2950.1610.2910.3560.3650.2440.3020.0980.2750.2630.253
Income Tax Expense 34.7731.0634.7223.9127.2222.0227.0738.436.6919.0323.0233.4640.6143.0937.6947.9140.1128.3414.80730.029.0549.3636.40542.5745.4337.22-1.82323.8217.413.98
Net Income 81.9963.3649.539.8440.8658.6945.31111.8669.4239.6877.2384.84106.23124.996.88123.4566.8257.1527.407115.1965.2483.87131.643128.0169.7486.2920.43327.6523.4821.01
Net Income Ratio 0.0980.0770.0620.0590.0580.0670.0670.1490.0950.0780.1370.1520.170.2080.1510.2170.1250.1430.0630.2270.1480.1870.2650.280.1630.2170.120.1480.1510.152
EPS 9.647.457.524.684.86.95.3313.158.164.199.089.9713.0814.6811.3914.517.856.723.2213.547.679.8615.4915.058.210.142.43.254.142.47
EPS Diluted 9.647.457.524.684.86.95.3313.157.774.199.089.9713.0814.6811.3914.517.856.723.2213.547.679.8615.4915.058.210.142.43.254.142.47
EBITDA 210188.75200.67111.45175.73155.08148.63231.5171.94105.53175.17178.08189.82194.17189.32224.48160.46125.95111.574210117.51181.48221.267204.74149.966157.08637.92271.1558.9950.99
EBITDA Ratio 0.2510.2150.2010.1840.2710.1920.2250.3350.2430.2390.2910.320.3030.3230.2870.3950.30.3160.2560.4140.2660.4050.4450.4480.3690.390.2230.380.380.368